摘要
目的观察生脉汤合血府逐瘀汤对保守治疗非ST段抬高型心肌梗死(NSTEMI)患者生物标志物的影响。方法连续性纳入本院行保守治疗的80例NSTEMI患者,按照整群随机化法分为对照组与观察组各40例。对照组患者给予指南推荐的西医治疗方案,观察组患者在西医治疗方案的基础上加用生脉汤合血府逐瘀汤,两组均连续治疗14 d。于治疗前后,检测两组患者的超敏C反应蛋白(hs-CRP)、降钙素原(PCT)、N末端B型利钠肽原(NT-proBNP)、纤维蛋白原(FIB)及D-二聚体水平,观察主要心血管不良事件(MACE)。结果观察组脱落7例(死亡1例),对照组脱落8例(死亡1例)。相对于治疗前,治疗后7、14 d时两组患者的血清hsCRP、PCT及血浆NT-proBNP、D-二聚体、FIB水平均持续降低,差异具有统计学意义(P <0.05);治疗7 d时,两组之间比较差异无统计学意义(P> 0.05);治疗14 d时,观察组的血清hs-CRP、PCT及血浆NT-proBNP、D-二聚体、FIB水平均明显低于对照组(P <0.05)。观察组患者的心绞痛发作次数明显低于对照组(P <0.05),其他MACE发生率比较差异无统计学意义(P> 0.05)。结论生脉汤合血府逐瘀汤能够明显改善保守治疗NSTEMI患者的炎症反应、高凝状态及心功能相关生物标志物水平,缓解心绞痛症状。
Objective:To observe the effect of Shengmai Decoction combined with Xuefu Zhuyu Decoction on biomarkers of patients with non-ST-segment elevation myocardial infarction(NSTEMI)who received conservative treatment. Methods:A total of 80 cases of NSTEMI patients who received conservative treatment in our hospital were successively included. According to cluster randomization,they were divided into the control group and observation group,with 40 cases in each group. The patients were given western medicine treatment regimen recommended by the guide in control group,and the patients were added with Shengmai Decoction combined with Xuefu Zhuyu Decoction on the basis of the western medicine treatment regimen in the observation group. Both groups were treated for 14 days consecutively. Before and after treatment,the levels of hypersensitive C-reactive protein(hs-CRP),procalcitonin(PCT),N-terminal pro-B-type natriuretic peptide(NT-proBNP),fibrinogen(FIB)and Ddimer were detected in two groups. The major cardiovascular adverse events(MACE)were observed. Results:There were 7 cases of loss(1 case of death)in the observation group,8 cases of loss(1 case of death)in the control group. Compared with before treatment,the serum levels of hs-CRP,PCT and plasma levels of NT-proBNP,Ddimer,FIB in two groups were continually decreased at 7 and 14 days after treatment,and the differences were statistically significant(P < 0.05). At 7 days after treatment,there was no significant difference between two groups(P > 0.05). At 14 days after treatment,the serum levels of hs-CRP,PCT and plasma levels of NT-proBNP,D-dimer,FIB in the observation group were significantly lower than those in control group(P < 0.05). The exerbation frequency of angina pectoris in the observation group was significantly lower than that in control group(P < 0.05);there was no significant difference in the incidence of other MACE between two groups(P > 0.05). Conclusion:Shengmai Decoction and Xuefu Zhuyu Decoction could significantly improve the biomarkers levels related to inflammatory response,hypercoagulability and cardiac function of NSTEMI patients who received conservative treatment,and alleviate the symptoms of angina pectoris.
作者
郑莹芊
彭廷云
袁华
Zheng Yingqian;Peng Tingyun;Yuan Hua(Hunan University of Chinese Medicine,Hunan,Changsha 410007,China)
出处
《中国中医急症》
2021年第9期1610-1613,共4页
Journal of Emergency in Traditional Chinese Medicine
基金
湖南中医药大学学科开放基金项目(2019HLX04)。
关键词
非ST段抬高型心肌梗死
生脉汤
血府逐瘀汤
保守治疗
生物标志物
主要心血管不良事件
Non-ST-segment elevation myocardial infarction
Shengmai Decoction
Xuefu Zhuyu Decoction
Conservative treatment
Biomarkers
Major cardiovascular adverse events
